Clinical Trial Update: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of HBM9161 (HL161) subcutaneous injection in generalized myasthenia gravis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• HBM9161 (HL161) (HBM9161)

Snippet

Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. | Conditions: Myasthenia Gravis | Phase 3 | Status: COMPLETED